000 | 01824 a2200517 4500 | ||
---|---|---|---|
005 | 20250516225529.0 | ||
264 | 0 | _c20150728 | |
008 | 201507s 0 0 eng d | ||
022 | _a2567-689X | ||
024 | 7 |
_a10.1160/TH13-06-0469 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aSchürmann, Daniel | |
245 | 0 | 0 |
_aC1-esterase inhibitor treatment: preclinical safety aspects on the potential prothrombotic risk. _h[electronic resource] |
260 |
_bThrombosis and haemostasis _cNov 2014 |
||
300 |
_a960-71 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aArterial Occlusive Diseases _xchemically induced |
650 | 0 | 4 | _aBlood Coagulation Tests |
650 | 0 | 4 |
_aComplement C1 Inhibitor Protein _xadministration & dosage |
650 | 0 | 4 | _aDisease Models, Animal |
650 | 0 | 4 | _aDose-Response Relationship, Drug |
650 | 0 | 4 | _aDrug Evaluation, Preclinical |
650 | 0 | 4 |
_aFactor XIIa _xanalysis |
650 | 0 | 4 |
_aFactor XIa _xanalysis |
650 | 0 | 4 | _aFemoral Artery |
650 | 0 | 4 |
_aFibrinolysis _xdrug effects |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aInfusions, Intravenous |
650 | 0 | 4 |
_aKallikrein-Kinin System _xdrug effects |
650 | 0 | 4 |
_aPlatelet Aggregation _xdrug effects |
650 | 0 | 4 | _aRabbits |
650 | 0 | 4 | _aThrombelastography |
650 | 0 | 4 |
_aThrombin _xbiosynthesis |
650 | 0 | 4 |
_aVenous Thrombosis _xchemically induced |
700 | 1 | _aHerzog, Eva | |
700 | 1 | _aRaquet, Elmar | |
700 | 1 | _aNolte, Marc W | |
700 | 1 | _aMay, Frauke | |
700 | 1 | _aMüller-Cohrs, Jochen | |
700 | 1 | _aBjörkqvist, Jenny | |
700 | 1 | _aDickneite, Gerhard | |
700 | 1 | _aPragst, Ingo | |
773 | 0 |
_tThrombosis and haemostasis _gvol. 112 _gno. 5 _gp. 960-71 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1160/TH13-06-0469 _zAvailable from publisher's website |
999 |
_c24080296 _d24080296 |